Quantbot Technologies LP Sells 16,778 Shares of Qiagen N.V. $QGEN

Quantbot Technologies LP reduced its stake in Qiagen N.V. (NYSE:QGEN) by 79.4% during the third quarter, HoldingsChannel reports. The firm owned 4,350 shares of the company’s stock after selling 16,778 shares during the quarter. Quantbot Technologies LP’s holdings in Qiagen were worth $194,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in QGEN. Smartleaf Asset Management LLC increased its position in Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares in the last quarter. MAI Capital Management boosted its position in Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after buying an additional 889 shares in the last quarter. Allworth Financial LP grew its stake in shares of Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after buying an additional 796 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Qiagen by 375.5% during the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after buying an additional 980 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its holdings in shares of Qiagen by 64.0% during the third quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock worth $71,000 after buying an additional 628 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

QGEN has been the subject of a number of research reports. JPMorgan Chase & Co. increased their price target on Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $59.00 target price on shares of Qiagen in a report on Thursday, February 5th. Citigroup dropped their target price on Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. TD Cowen reissued a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Finally, Deutsche Bank Aktiengesellschaft lowered Qiagen from a “buy” rating to a “hold” rating and lifted their price target for the company from $52.00 to $54.00 in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $55.20.

Qiagen Price Performance

QGEN stock opened at $41.15 on Thursday. The company has a market capitalization of $8.69 billion, a P/E ratio of 20.41, a PEG ratio of 2.10 and a beta of 0.70. The company has a fifty day moving average price of $49.58 and a 200-day moving average price of $48.99. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. Qiagen N.V. has a 52-week low of $40.14 and a 52-week high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.01. The company had revenue of $540.42 million for the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. Qiagen’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.61 earnings per share. As a group, equities analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.